Results of ongoing clinical trials will be required to assess the efficacy of IDH1 inhibitors in reducing 2-HG levels and improving clinical outcomes for ICC patients with such IDH1 mutations. This evidence concerns the gene IDH1 and intrahepatic cholangiocarcinoma.